Dissociatives: Ketamine, PCP, DXM, Nitrous
Ketamine is now an FDA-approved antidepressant. It's also a recreational drug with an emerging use disorder pattern. Both are true.
Body — 8 lenses: [Science: NMDA receptor antagonism (ketamine, PCP, DXM), nitrous as N2O NMDA + opioid. Biology: dissociation at moderate doses; K-hole at higher; ketamine bladder toxicity with chronic recreational use; B12 deficiency and neuropathy from nitrous. Psychology: dissociative experience; emerging ketamine use disorder pattern; the therapy/recreation confusion. Policy: ketamine Schedule III; esketamine (Spravato) FDA-approved for TRD; nitrous legal and lightly regulated; PCP Schedule II. Trends: ketamine clinics exploding; WhipIt+ canister culture; DXM abuse among adolescents declining. Social: the “ketamine therapy” wellness wave, Matthew Perry’s death and accountability. Treatment: ketamine use disorder — sparse evidence, harm-reduction-heavy approach. Harm reduction: nitrous B12 supplementation, ketamine urinary-tract monitoring, don’t mix dissociatives with depressants.]
Sources Cited
- 01.Ahttps://clinicaltrials.govClinicalTrials.gov
- 02.A
Filed Under
sciencebiologypsychologypolicytrendssocial-culturaltreatmentharm-reductionPeer-Reviewed Research
Continue reading
More from this section
The Ego Goes Quiet, and So Does the Pattern: What Psychedelics Actually Do to the Psychology of Addiction
Psilocybin suppresses the default mode network. MDMA reduces amygdala reactivity during trauma processing. Ibogaine resets mu-opioid signaling. Here’s what the science says about the psychology of psychedelic therapy for addiction.
Science & MedicineFrance Just Approved IV Ketamine for Suicidal Crisis. The US Has an Excuse, Not an Answer.
France’s ANSM became the first national regulator anywhere to authorize IV racemic ketamine for adult acute suicidal crisis. The US approved esketamine in 2019 but won’t standardize IV ketamine—because it’s a generic with no commercial sponsor.
Science & MedicineThe FDA Just Cleared the First US Ibogaine Trial. It Took 30 Years.
DemeRx received FDA IND clearance for noribogaine—an ibogaine metabolite—for alcohol use disorder. Dr. Deborah Mash has been waiting three decades for this regulatory opening.